Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Drug vials The majority of oncology drugs (70 percent) will be high-cost orphan drugs–focused on relatively small group of patients with rare subsets of cancer. (Photo: Shutterstock)

A new report says the FDA will evaluate more than 150 new drugs for approval in 2020, with 11 drugs representing potential blockbuster sales of more than $1 billion each.


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.